Athira Pharma Inc. is a biopharmaceutical company at the forefront of developing innovative therapies for neurodegenerative diseases, with a particular focus on Alzheimer's disease. Founded in 2011 and headquartered in Seattle, Washington, the company is dedicated to advancing scientific research and creating novel treatments that address the underlying causes of neurological disorders.
The cornerstone of Athira's approach lies in its commitment to developing therapies that target the regeneration and restoration of brain cells. The company's lead therapeutic candidate, ATH-1017, is designed to promote neuronal repair and improve cognitive function in patients with Alzheimer's disease and other neurodegenerative conditions. This novel mechanism of action sets Athira apart in the field of neurology and positions it as a potential pioneer in treating Alzheimer's disease.
Athira's development efforts are backed by rigorous scientific research and clinical trials. The company collaborates with leading researchers, clinicians, and experts in the field to ensure the validity and effectiveness of its therapeutic candidates. Athira's commitment to evidence-based medicine and robust clinical development is integral to its mission of bringing innovative solutions to patients in need.
The company's leadership is driven by Dr. Leen Kawas, the CEO and President, who has been instrumental in guiding Athira's growth and strategic direction. Dr. Kawas' background in neuroscience and dedication to advancing neurological therapies underscores the company's focus on making meaningful contributions to patient care.